Candel Therapeutics (CADL) Liabilities and Shareholders Equity (2020 - 2025)

Candel Therapeutics has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $125.2 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 17.15% year-over-year to $125.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $420.7 million (up 126.06% YoY) and the FY2025 annual result came in at $125.2 million, up 17.15% from the prior year.
• Liabilities and Shareholders Equity advanced to $125.2 million in Q4 2025 per CADL's latest filing, from $93.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $125.2 million in Q4 2025 and troughed at $21.5 million in Q3 2024.
• A 5-year average of $73.5 million and a median of $85.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 57.02% in 2024, then jumped 335.0% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $89.2 million in 2021, then dropped by 12.91% to $77.7 million in 2022, then plunged by 46.97% to $41.2 million in 2023, then surged by 159.38% to $106.9 million in 2024, then climbed by 17.15% to $125.2 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $125.2 million, $93.6 million, and $106.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.